| HER-2 functions as an oncogene in SKOV3 human ovarian carcinoma cells. | ovarian, |
| Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth of murine breast cancer. | oral,breast, |
| Correlations between Her2 oncoprotein, VEGF expression, MVD and clinicopathological parameters in gastric cancer. | gastric, |
| An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival. | skin, |
| Dysregulation of miR-125a-5p/125b and HER2 is an early event in the gastric (intestinal-type) and esophageal (Barrett) oncogenesis. | gastric,esophageal, |
| Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer. | breast, |
| Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). | uterine, |
| Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. | breast, |
| Findings strongly suggest that mutations in the transmembrane domain of HER2 may be oncogenic, causing hereditary and sporadic lung adenocarcinomas. | lung, |
| n-Butyrate increases c-erb A oncogene expression in human colon fibroblasts. | colorectal, |
| HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. | gastric, |
| Correlation of Wilms tumor 1 isoforms with HER2 and ER-alpha and its oncogenic role in breast cancer. | breast, |
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. | breast,ovarian, |
| Absence of EGFR, ERBB2 and ERBB4 mutation homologous to the oncogenic ERBB3 Val-104 mutation in colorectal cancers. | colorectal, |
| Modeling time-dependent transcription effects of HER2 oncogene and discovery of a role for E2F2 in breast cancer cell-matrix adhesion. | breast, |
| Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer. | breast, |
| Results show that poly (ADP-ribose) polymerase (PARP) inhibition has antitumour effects and increases trastuzumab activity in oncogene protein HER2 overexpressing breast cancer. | breast, |
| Oncogene addiction and immunity: clinical implications of tumour infiltrating lymphocytes in breast cancers overexpressing the HER2/neu oncogene. | breast, |
| Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. | esophageal, |
| [DNA structural features on the borders of ERBB2 amplicons in breast cancer]. | breast, |